ARS Pharmaceuticals, Inc. Operating Cash Flow
ARS Pharmaceuticals, Inc. (SPRY) reported Operating Cash Flow of -$105.87 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-13
- ARS Pharmaceuticals, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$60.93M.
- ARS Pharmaceuticals, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$44.95M.
- ARS Pharmaceuticals, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$43.48M, a 203.53% decline year-over-year.
- ARS Pharmaceuticals, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$47.05M.
- ARS Pharmaceuticals, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$170.87M, a 1361.19% decline from fiscal 2024.
- ARS Pharmaceuticals, Inc. net cash provided by (used in) operating activities for fiscal 2024 was $13.55M.
- ARS Pharmaceuticals, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$59.27M.
- ARS Pharmaceuticals, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$40.08M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 3 month as first filed | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 6 month as first filed | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 9 month as first filed | Net Cash Provided by (Used in) Operating Activities 12 month | Net Cash Provided by (Used in) Operating Activities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$60.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$105.87M 10-Q · filed 2026-08-13 | -$149.36M derived: sum of 3 quarters · filed 2026-08-13 | -$196.41M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2026-03-31 | -$44.95M 10-Q · filed 2026-05-15 | -$88.43M derived: sum of 2 quarters · filed 2026-05-15 | -$135.48M derived: sum of 3 quarters · filed 2026-05-15 | -$175.07M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-12-31 | -$43.48M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | -$90.53M derived: sum of 2 quarters · filed 2026-03-09 | -$130.12M derived: sum of 3 quarters · filed 2026-08-13 | -$170.87M 10-K · filed 2026-03-09 | ||||
| 2025-09-30 | -$47.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$86.64M derived: sum of 2 quarters · filed 2026-08-13 | -$127.38M 10-Q · filed 2025-11-10 | -$85.38M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-06-30 | -$39.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$80.33M 10-Q · filed 2026-08-13 | -$38.33M derived: sum of 3 quarters · filed 2026-08-13 | -$52.80M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-03-31 | -$40.74M 10-Q · filed 2026-05-15 | $1.26M derived: sum of 2 quarters · filed 2026-05-15 | -$13.21M derived: sum of 3 quarters · filed 2026-05-15 | -$20.48M derived: sum of 4 quarters · filed 2026-05-15 | ||||
| 2024-12-31 | $42.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $27.54M derived: sum of 2 quarters · filed 2026-03-09 | $20.26M derived: sum of 3 quarters · filed 2026-03-09 | $13.55M 10-K · filed 2026-03-09 | ||||
| 2024-09-30 | -$14.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$21.75M derived: sum of 2 quarters · filed 2025-11-10 | -$28.46M 10-Q · filed 2025-11-10 | -$45.86M derived: sum of 4 quarters · filed 2025-11-10 | ||||
| 2024-06-30 | -$7.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$13.99M 10-Q · filed 2025-08-13 | -$31.39M derived: sum of 3 quarters · filed 2025-08-13 | -$44.16M derived: sum of 4 quarters · filed 2025-08-13 | ||||
| 2024-03-31 | -$6.71M 10-Q · filed 2025-05-14 | -$24.11M derived: sum of 2 quarters · filed 2025-05-14 | -$36.88M derived: sum of 3 quarters · filed 2025-05-14 | -$53.55M derived: sum of 4 quarters · filed 2025-05-14 | ||||
| 2023-12-31 | -$17.41M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | -$30.17M derived: sum of 2 quarters · filed 2025-03-20 | -$46.84M derived: sum of 3 quarters · filed 2025-03-20 | -$59.27M 10-K · filed 2025-03-20 | ||||
| 2023-09-30 | -$12.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$29.43M derived: sum of 2 quarters · filed 2024-11-13 | -$41.86M 10-Q · filed 2024-11-13 | -$62.36M derived: sum of 4 quarters · filed 2024-11-13 | ||||
| 2023-06-30 | -$16.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$29.10M 10-Q · filed 2024-08-06 | -$49.59M derived: sum of 3 quarters · filed 2024-08-06 | -$55.28M derived: sum of 4 quarters · filed 2024-08-06 | ||||
| 2023-03-31 | -$12.43M 10-Q · filed 2024-05-09 | -$32.93M derived: sum of 2 quarters · filed 2024-05-09 | -$38.61M derived: sum of 3 quarters · filed 2024-05-09 | -$45.58M derived: sum of 4 quarters · filed 2024-05-09 | ||||
| 2022-12-31 | -$20.50M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | -$26.18M derived: sum of 2 quarters · filed 2024-03-21 | -$33.15M derived: sum of 3 quarters · filed 2024-03-21 | -$40.08M 10-K · filed 2024-03-21 | ||||
| 2022-09-30 | -$5.68M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$12.66M derived: sum of 2 quarters · filed 2023-11-09 | -$19.58M 10-Q · filed 2023-11-09 | -$51.48M 10-Q · filed 2022-11-02 | $8.31M derived: sum of 4 quarters · filed 2023-11-09 | |||
| 2022-06-30 | -$6.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$13.90M 10-Q · filed 2023-08-10 | -$34.90M 10-Q · filed 2022-08-11 | $13.99M derived: sum of 3 quarters · filed 2023-08-10 | -$5.12M derived: sum of 4 quarters · filed 2023-08-10 | |||
| 2022-03-31 | -$6.92M 10-Q · filed 2023-05-15 | -$19.74M 10-Q · filed 2022-05-12 | $20.97M derived: sum of 2 quarters · filed 2023-05-15 | $1.85M derived: sum of 3 quarters · filed 2023-05-15 | -$12.29M derived: sum of 4 quarters · filed 2023-05-15 | |||
| 2021-12-31 | $27.89M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $8.78M derived: sum of 2 quarters · filed 2023-03-23 | -$5.36M derived: sum of 3 quarters · filed 2023-03-23 | -$17.56M 10-K · filed 2023-03-23 | -$66.76M 10-K · filed 2022-03-31 | |||
| 2021-09-30 | -$19.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | -$33.25M derived: sum of 2 quarters · filed 2022-11-02 | -$45.45M 10-Q · filed 2022-11-02 | -$56.55M derived: sum of 4 quarters · filed 2022-11-02 | ||||
| 2021-06-30 | -$14.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$26.34M 10-Q · filed 2022-08-11 | -$37.43M derived: sum of 3 quarters · filed 2022-08-11 | -$44.46M derived: sum of 4 quarters · filed 2022-08-11 | ||||
| 2021-03-31 | -$12.20M 10-Q · filed 2022-05-12 | -$23.30M derived: sum of 2 quarters · filed 2022-05-12 | -$30.33M derived: sum of 3 quarters · filed 2022-05-12 | -$35.77M derived: sum of 4 quarters · filed 2022-05-12 | ||||
| 2020-12-31 | -$11.10M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | -$18.13M derived: sum of 2 quarters · filed 2022-03-31 | -$23.57M derived: sum of 3 quarters · filed 2022-03-31 | -$31.20M 10-K · filed 2022-03-31 | ||||
| 2020-09-30 | -$7.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$12.47M derived: sum of 2 quarters · filed 2021-11-10 | -$20.10M 10-Q · filed 2021-11-10 | |||||
| 2020-06-30 | -$5.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | -$13.07M 10-Q · filed 2021-08-12 | ||||||
| 2020-03-31 | -$7.63M 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |